Details
Stereochemistry | ACHIRAL |
Molecular Formula | C25H37N5O3 |
Molecular Weight | 455.593 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC(=O)N1CCC(CN2CCC(CNC(=O)C3=C4NC(=NC4=CC=C3)C(C)C)CC2)CC1
InChI
InChIKey=MZOITCJKGUIQEI-UHFFFAOYSA-N
InChI=1S/C25H37N5O3/c1-17(2)23-27-21-6-4-5-20(22(21)28-23)24(31)26-15-18-7-11-29(12-8-18)16-19-9-13-30(14-10-19)25(32)33-3/h4-6,17-19H,7-16H2,1-3H3,(H,26,31)(H,27,28)
TD 8954 (also known as TAK 954) is a selective serotonin 5-HT(4) receptor agonist. It is known a potential role for potent and efficacious 5-HT(4) receptor agonists in the treatment of Alzheimer's disease (AD). TD 8954 participated in phase I clinical trials to study its potential role in the treatment of AD. However, this study was discontinued. In addition, TD 8954 is involved in phase II clinical trials to investigate its effect on gastrointestinal and colonic transit in diabetic or idiopathic gastroparesis participants and for the prophylaxis and treatment of postoperative gastrointestinal dysfunction in participants undergoing large- and small-bowel resection.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Participation of 5-HT3, 5-HT4, and nicotinic receptors in the peristaltic reflex of guinea pig distal colon. | 1996 Nov |
|
Signal transduction pathways for serotonin as an intestinal secretagogue. | 1997 Oct |
|
Serotonin: a mediator of the brain-gut connection. | 2000 Oct |
|
Rationale for using serotonergic agents to treat irritable bowel syndrome. | 2005 Apr 1 |
|
The serotonin signaling system: from basic understanding to drug development for functional GI disorders. | 2007 Jan |
|
The Pharmacology of TD-8954, a Potent and Selective 5-HT(4) Receptor Agonist with Gastrointestinal Prokinetic Properties. | 2011 |
|
Discovery of TD-8954, a clinical stage 5-HT(4) receptor agonist with gastrointestinal prokinetic properties. | 2013 Jul 15 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT03281577
TAK-954 0.1; 0.3; 1 milligram (mg), 60-minute infusion, intravenous (IV), once daily for up to 3 days.
Route of Administration:
Intravenous
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB12725
Created by
admin on Sat Dec 16 18:17:57 GMT 2023 , Edited by admin on Sat Dec 16 18:17:57 GMT 2023
|
PRIMARY | |||
|
C171900
Created by
admin on Sat Dec 16 18:17:57 GMT 2023 , Edited by admin on Sat Dec 16 18:17:57 GMT 2023
|
PRIMARY | |||
|
916075-84-8
Created by
admin on Sat Dec 16 18:17:57 GMT 2023 , Edited by admin on Sat Dec 16 18:17:57 GMT 2023
|
PRIMARY | |||
|
11961293
Created by
admin on Sat Dec 16 18:17:57 GMT 2023 , Edited by admin on Sat Dec 16 18:17:57 GMT 2023
|
PRIMARY | |||
|
JK-21
Created by
admin on Sat Dec 16 18:17:57 GMT 2023 , Edited by admin on Sat Dec 16 18:17:57 GMT 2023
|
PRIMARY | |||
|
300000038048
Created by
admin on Sat Dec 16 18:17:57 GMT 2023 , Edited by admin on Sat Dec 16 18:17:57 GMT 2023
|
PRIMARY | |||
|
11124
Created by
admin on Sat Dec 16 18:17:57 GMT 2023 , Edited by admin on Sat Dec 16 18:17:57 GMT 2023
|
PRIMARY | |||
|
35F0Y2W16Q
Created by
admin on Sat Dec 16 18:17:57 GMT 2023 , Edited by admin on Sat Dec 16 18:17:57 GMT 2023
|
PRIMARY |
ACTIVE MOIETY